# A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093

> **NCT02171234** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 32 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Placebo
- **DRUG:** BIA 2-093

## Key facts

- **NCT ID:** NCT02171234
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02
- **Primary completion:** 2001-06
- **Final completion:** 2001-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2015-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02171234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02171234, "A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02171234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*